Zealand Pharma reports data from Phase III short bowel syndrome trial

Zealand Pharma has reported positive topline data from the Phase III EASE 1 clinical trial of glepaglutide to treat short bowel syndrome (SBS) patients.

The double-blind, randomised trial analysed the safety and efficacy of 10mg of subcutaneous glepaglutide given once or twice a week versus a placebo.